Document Detail

Severe flucloxacillin induced acute generalised exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features; does overlap between AGEP and TEN exist? Clinical report and review of the literature.
MedLine Citation:
PMID:  24888401     Owner:  NLM     Status:  Publisher    
Acute Generalised Exanthematous Pustulosis (AGEP) and Stevens Johnson syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) are rare but severe cutaneous adverse drug reactions. Especially in TEN, large areas of the skin and mucosae may become detached. Although AGEP and SJS/TEN are distinct entities with a different clinical picture, pathogenesis, prognosis, and treatment, they may share some features, raising the hypothesis of overlap between both entities. We present a severe case of AGEP, caused by flucloxacillin, clinically presenting with toxic epidermal necrolysis-like features and pronounced systemic symptoms with haemodynamic and respiratory instability. Besides, we present a review of the literature on cases of AGEP with features resembling SJS/TEN or a supposed overlap with SJS/TEN. This article is protected by copyright. All rights reserved.
S van Hattem; G I Beerthuizen; S H Kardaun
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-2
Journal Detail:
Title:  The British journal of dermatology     Volume:  -     ISSN:  1365-2133     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
This article is protected by copyright. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  GC-MS-Based Metabolite Profiling of Cosmos caudatus Leaves Possessing Alpha-Glucosidase Inhibitory A...
Next Document:  Consequences of Patient Access Restrictions to Branded Oxycodone Hydrochloride Extended-Release Tabl...